# **Diabetes Management System**

## Prior Authorization Request Form



ONLY COMPLETED FORMS CAN BE PROCESSED

#### Harvard Pilgrim reserves the right to request additional clinical information.

Please complete and submit your request online using HPHConnect for providers. Register for *HPHConnect* online at <a href="https://www.harvardpilgrim.org/providers">www.harvardpilgrim.org/providers</a>. If you have any questions about this process, please contact the Provider Service Center at 800-708-4414. **FAX completed form to 800-232-0816**.

Member name										
Member ID # (Harvard Pilgrim HMO, PPO, POS)				Date of b	oirth /	1				
Requesting provider na	me					NPI#				
Requesting provider fax			Phone							
Requested setting:	Surgical day care	Other (describe)								
Facility name/location										
Facility NPI #										
Planned date of service	1 1									
Diagnosis: ICD-10 code	:									
Diagnosis Codes										
CPT Requested Codes:	(Codes in policy i	but not billed by s	ervicing prov	rider – DME bu	t MD office:	95249, 95	250)			
A4255 A425	56 A9274	A9276	A9277	A9278	E0784					
Currently on insulin pump therapy: Y N Typ						How lor	ng			
Currently using CGM:	Y N Ty	ре			How long					
Last 2 HgAic readings:										
Result							Date	/	1	
Result							Date	/	1	
How often does member	er check his BG lev	els ( <i>please subn</i>	nit logs)							

#### Intermittent/Professional Continuous Glucose Monitors

Continuous Glucose Monitoring Systems Designed and Used for Professional Monitoring (must have all)

Use of the monitor will be over a set period of three consecutive days

When not used more than once in the preceding twelve-month period

A physician is supervising monitoring and interpretation, <u>any</u> of the following indications

Type I or type 2 diabetes mellitus (Must have all)

Glycemic control is inadequate, as indicated by either:

Glycosylated hemoglobin (HbA1c) proportion in excess of seven percent on multiple consecutive readings in the past two months, <u>or</u>

Recurrent severe hypoglycemia (less than 50mg/dl)

Glycemic control inadequacy has persisted despite a frequently modified insulin administration and self-monitoring regimen

Use of an insulin pump or injection of insulin at least thrice daily has been necessary

Member is compliant with self-monitoring, generally indicated by self-monitoring being performed at a frequency of at least four self-tests per day

Suspected primary islet cell hypertrophy (nesidioblastosis) or persistent hyperinsulinemic hypoglycemia of infancy (PHHI, congenital hypoglycemia) supported by consistent symptoms

Need for established basal insulin levels with which to calibrate an imminent insulin pump initiation

Pregnancy or imminent pregnancy and either of the following:

Type I diabetes requiring insulin therapy

Gestational diabetes requiring insulin therapy

April 2018 1

## Diabetes Management System Prior Authorization Request Form (cont.)

### **Long-term Personal Glucose Monitors**

Type I Diabetes (must have all)

Ability to use system or access to a caregiver who has such ability, and

Inadequately controlled blood glucose, indicated by either of the following:

Glycosylated hemoglobin (HbA1c) proportion in excess of seven percent on multiple consecutive readings in the past two three months,  $\underline{or}$ 

Recurrent severe hypoglycemia (less than 50mg/dl)

Persistence of inadequate glucose control despite **both** of the following:

Frequently modified insulin administration and self-monitoring regimen

Member compliance, generally shown by frequent (at least four times daily) self-monitoring, and

Use of an insulin pump or injection of insulin at least thrice daily has been necessary

Type I Diabetes During Pregnancy (must have all)

Inadequately controlled blood glucose, indicated by either:

Glycosylated hemoglobin (HbA1c) proportion in excess of seven percent on multiple consecutive readings in the past two three months, *or* 

Recurrent severe hypoglycemia (less than 50mg/dl)

Use of an insulin pump or injection of insulin at least thrice daily has been necessary, and

Member is compliant with self-testing, typically demonstrated by frequent (at least four times daily) self-monitoring measurements.

### **Insulin Pumps**

Poorly Controlled Diabetes (must have all)

Diabetes Type I, or

Diabetes Type II and C-peptide testing showing both

Results showing either:

Fasting C-peptide level of no greater than double the lower limit of normal in the laboratory measurement method when the member with renal insufficiency and a creatine clearance no greater than 50ml/minute, <u>or</u>

Fasting BG obtained concurrently to the C-Peptide level is no greater than 225 mg/dl

Prior attempts to bring diabetes under control (must have <u>all</u>)

Insulin injections have been required at a frequency of at least three administrations per day

Blood glucose measurements have been required at a frequency of at least four per day

Completion of a comprehensive diabetes and self-management education program in recent years;

Multiple adjustments to insulin administration and self-monitoring regimens

Frequent self-adjustment of insulin dose

Persistence of any of the following:

Glycosylated hemoglobin (HbA1c) proportion in excess of seven percent on multiple consecutive readings in the past two months

Recurrent hypoglycemia or ketoacidosis resulting in hospitalization

Recurrent hypoglycemia or severe glycemic excursion

Widely fluctuating blood glucose concentrations leading up to mealtimes

Frequent early morning blood glucose increases ("dawn phenomena") in excess of 200mg/dl;

Passage of an assessment of amenability to proper device use, including training, self-care processes and follow-up Successful use of an insulin infusion pump obtained prior to enrollment and a documented glucose self-testing frequency of at least 4 times per day during the month leading up to enrollment, <u>or</u>

Gestational diabetes endangering fetal health

April 2018 2

## **Diabetes Management System** Prior Authorization Request Form (cont.)

### **Sensor-Augmented Pump Therapy**

Sensor-augmented pump therapy, commonly called "artificial pancreases," such as the Minimend 530G, 630G, and 670G and Animas Vibe (Must have *all* indications criteria).

Member qualifies for both an insulin pump and a long-term continuous glucose monitor

Member is in need of a new device due to <u>any</u> of the following:

Scheduled replacement of device previously approved by Harvard Pilgrim

New qualification

Persistent insufficient glycemic control, defined as either:

Glycated hemoglobin (HbA1c) concentrations between seven and ten percent on multiple consecutive readings in the past two months,  $\underline{or}$ 

Recurrent severe hypoglycemia (less than 50mg/dl)

Member is willing and able to self-monitor his/her long-tern diabetes stability (must have all)

Taking four blood glucose concentration observations (either through device CGM capability or Fingerstix) per day Maintaining contact with his/her primary healthcare provider

Notice warnings, signals, alerts, and alarms from the device (please see section on enhancements and accommodations for visual and auditory impairments)

System requires interaction for post-meal bolusing and retains the functionality of both a standalone glucose monitor and insulin pump.

### Enhancements and Accommodations for the Visually and/or Auditorily Impaired

Accessories to, software for, and specialized models of continuous glucose monitoring systems designed to accommodate visual or auditory impairments (Must have <u>all</u>)

Member has a visual or auditory impairment that precludes the successful use of a standard model without assistance beyond initial setup and instruction.

The standard model does not come with accommodations sufficient to allow successful independent use.

The accommodation feature being requested is appropriate for the needs of the member.

#### Replacement

Replacement of a continuous glucose monitoring system, insulin pump, or combined system (Must have <u>all</u>)

Documentation is in the form of clinical notes or letters generated by a clinician overseeing the member's diabetic condition. The present monitor has been rendered ineffective or inoperable due to *either*:

A change in member condition that the current monitor is unable to accommodate

Being damaged by events outside the control of the user

Continued use of the device is supported

Device replacement cannot be obtained from the manufacturer or supplier due the expiration of device warranty

Loss/damage is not attributable to abuse, sabotage, or neglect on the part of the user, and

The cost of replacement rather than repair is justified by the nature of damage and useful lifetime of the device

The replacement is not an additional/backup monitor

The replacement monitor is synonymous to the monitor being replaced unless replacement has been necessitated by a change in member condition the old device is unable to accommodate

April 2018 3